Posts for Ticker ‘FACT’

Top Day Trader Alerts (SWHC, RGR, TTWO, BAC, MRVL, BRCM, TXN, FACT, JAVA)

These are this morning’s top day trader and active trader alert stocks.  We have more detailed volume data and analysis on each stock story via a link over to VSInvestor.com:

Smith & Wesson Holding Corp. (NASDAQ: SWHC) is off 12% on earnings and guidance; we’d watch for added fallout in Sturm, Ruger & Co. Inc. (NYSE: RGR).

Take-Two Interactive Software (NASDAQ: TTWO) is down 20% on its warning.

Bank of America Corp. (NYSE: BAC) is trading down 1.7%, but not as much as the deal price, after increasing its capital raise.

Marvell Technology Group Ltd. (NASDAQ: MRVL) is at new 52-week highs after higher earnings and higher guidance.  We’d watch Broadcom Corporation (NASDAQ: BRCM) and Texas Instruments Inc. (NYSE: TXN) on the news.

Facet Biotech Corporation  (NASDAQ: FACT) is down slightly despite a boosted buyout offer.

Sun Microsystems, Inc. (NASDAQ: JAVA) is up over 5% on a report that the EU may be flawed and/or appeased in its block of the Oracle deal.

You can join our open email distribution list to hear more news on key analyst calls, top day trader alerts, mergers and acquisitions, Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Posted on: December 4, 2009 – 8:52 am in Pre-Market Activity, Trading Alert, , , , , , , , ,

BioTech Hostile Takeover: Biogen Plays For Facet

Facet Biotech Corporation (FACT) confirms that it is in receipt of Biogen Idec Inc.’s (BIIB) letter dated September 4, 2009 offering $14.50 per share for all of the outstanding shares of Facet.

Facet shares rocketed 75% to $15.75 after being halted briefly. So far this year, Facet’s shares have traded as low as $6 and as high as $11, so the deal is at a significant premium.

The deal is hostile. Biogen has asked to meet with the Facet board.

Reuters reports that“Biogen Idec said the offer was lower than an initial offer of $15 per share it had made on Aug. 17 to Facet Chief Executive Officer Faheem Hasnain, followed by a letter from Biogen Idec to Hasnain and Facet’s board on Aug. 21 offering that price.”

A recent deal between Facet and Trubion Pharmaceuticals (TRBN) which Facet believed was in its best interests was not taken well by shareholders who have pushed the stock down.

Biogen and Facet are  jointly developing a drug for multiple sclerosis and a treatment for solid tumors.

Facet is low on cash and the company’s management has indicated that it may have to bring in new funds in a year.

Douglas A. McIntyre

For more biotech news visit BioHealthInvestor.com

Posted on: September 4, 2009 – 3:48 pm in Biotech, Mergers and Buy Outs, , ,

Broadpoint Securities Registers Shares Tied To Recent Private Placement (BPSG, FACT)

Broadpoint Securities (NASDAQ: BPSS) has filed on behalf of stockholders a securities offering whereby an aggregate of 7.058 million shares of common stock for a total maximum price of $12.352 million.

The independent boutique investment bank will not receive any proceeds  from the offering.  This securities registration is tied to a private placement that Broadpoint sold to accredited investors in early March.

We frequently discuss secondary offerings, special financings, restructurings, insider activity, activist investor trends, IPO’s, back door plays into IPO’s, SPAC’s, spin-offs, and more on our open email distribution list.

Broadpoint has a $127 million market cap and had recently completed some private placements of securities.  For those of you who aren’t familiar with Broadpoint, this is the one that used to First Albany Securities that used to trade as "FACT" on NASDAQ.

Its 52-week trading range is $0.99 to $1.96.  Back in 2005 this was north of $5.00 and back in 2003 and 2004 this traded north of $15.00 for a brief period of time.

Rachel Lopez
April 2, 2008

Posted on: April 2, 2008 – 10:29 am in Brokerage Firms, Secondary Offering, ,

Pre-Market Stock News (May 14, 2007)

(ACL) Alcan’s buyout bid by Alcoa is reportedly getting big interest from larger names such as Rio Tinto and others.
(BRLC) Syntax-Brillian filed to sell 25.6M shares, although the shelf was telegraphed with earnings last week.
(DCX) DaimlerChrysler is selling a majority stake in Chrysler to Cerberus Capital for $7.7 Billion; Chrysler will maintain 19.9% stake.
(FACT) First Albany is recapitalizing and will receive a $50M investment from Matlin Patterson.
(GE) GE’s NBC unit could or should merge with Yahoo! (YHOO) according to WSJ.
(GILT) Gilat Satellite $0.13 EPS vs $0.11e.
(INFT) Inforte gets a $4.25 cash buyout from Business & Decision.
(MMC) Marsh & McClennan announced $500M accelerated share buyback program.
(MRK) Merck received and FDA Approvable letter of its NDA for EMEND.
(MWA) Mueller Water names new CFO.
(MYL) Mylan Labs is acquiring Merck KGaA’s generic operations for about $6.7 Billion.
(NAT) Nordic American Tanker $0.85 EPS vs $0.83e.
(NAVR) Navarre is selling its independent music distribution business.
(PLXS) Plexus CFO retiring.
(QTWW) Quantum Fuel signed an agreement to acquire a 24.9% stake in a German solar company.
(SORC) Source Interlink to acquire PRIMEDIA’s Enthusiast Media unit for about $1.2 Billion.
(SYNF) Synergy Financial being acquired by New York Community Bancorp (NYB).
(TRMK) Trimark is paying $85M to acquire DATA RETURN from Saratoga Partners.
(ULBI) Ultralife Battery accepts modified order from last week lowered from $6.9M to $2.4M.
(USBE) US Bioenergy $0.08 EPS vs $0.21e.
(VAS) VIASYS being acquired by Cardinal Health (CAH) for $42.75.
(WMT) Wal-Mart is expanding electronics offerings and will include Skype equipment.

Jon C. Ogg
May 14, 2007

Posted on: May 14, 2007 – 6:35 am in Pre-Market Activity, , , , , , , , , , , , , ,